INS and metabolic syndrome: Our group has reported that in the metabolic syndrome model (30% sucrose intake), the fenofibrate therapy significantly reduced Ang II concentration and downregulated the Ang II signaling pathway, in addition to decreasing myocardial fibrosis and restoring local insulin sensitivity [7,52].